BXP.L Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 14:19):

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh...

Stats
Dagens volum	1 080.00
Gjennomsnittsvolum	46 037.00
Markedsverdi	169.52M
EPS	£2.13 ( 2023-03-31 )
Last Dividend	£3.32 ( 2022-11-17 )
Next Dividend	£0 ( N/A )
P/E	4.22
ATR14	£0 (0.00%)

Beximco Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
POLX.L	0.931
FRP.L	0.923
FWD.L	0.921
KCT.L	0.92
SENS.L	0.917
GRIO.L	0.917
RESI.L	0.915
WNWD.L	0.914
GSF.L	0.913
WATR.L	0.912

10 Mest negative korrelasjoner
RR.L	-0.933
REL.L	-0.932
RSVL.L	-0.928
IL0A.L	-0.922
JDW.L	-0.917
FEDF.L	-0.911
XFFE.L	-0.91
MPO.L	-0.91
JREC.L	-0.909
EMRJ.L	-0.906

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Beximco Pharmaceuticals Økonomi

Annual	2022
Omsetning:	£39.27B
Bruttogevinst:	£17.31B (44.09 %)
EPS:	£10.34

FY	2022
Omsetning:	£39.27B
Bruttogevinst:	£17.31B (44.09 %)
EPS:	£10.34

FY	2022
Omsetning:	£34.67B
Bruttogevinst:	£15.81B (45.61 %)
EPS:	£11.48

FY	2021
Omsetning:	£29.49B
Bruttogevinst:	£13.92B (47.21 %)
EPS:	£11.49

Financial Reports:

No articles found.

Beximco Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£0 (N/A)	£3.32 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

Beximco Pharmaceuticals Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.98 - Stable (19.61%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£0.174	2008-06-30
Last Dividend	£3.32	2022-11-17
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	£16.75	--
Avg. Dividend % Per Year	1.38%	--
Score	3.34	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.98
Div. Directional Score	8.25	--

Next Divdend (Est)
(2024-05-24)

£0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

3.34

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2008	£0.174	1.17%
2009	£0.405	6.62%
2010	£0	0.00%
2011	£0	0.00%
2012	£0	0.00%
2013	£0	0.00%
2014	£0	0.00%
2015	£1.057	7.02%
2016	£1.730	7.40%
2017	£1.373	2.80%
2018	£1.354	2.48%
2019	£1.605	3.92%
2020	£1.766	4.37%
2021	£3.97	4.14%
2022	£3.32	2.69%
2023	£0	0.00%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SCF.L	Dividend Knight	2023-07-06	Quarterly	30	2.18%
HUR.L	Dividend King	2023-06-08	Insufficient data to determine frequency	2	21.63%
BERI.L	Dividend Knight	2023-09-28	Quarterly	19	2.36%
WINK.L	Dividend King	2023-07-20	Quarterly	15	3.81%
NAIT.L	Dividend Knight	2023-07-20	Quarterly	53	2.33%
EDIN.L	Dividend King	2023-06-08	Quarterly	53	2.46%
SNWS.L	Dividend Knight	2023-06-08	Annually	32	4.00%
ITRK.L	Dividend Knight	2023-09-14	Semi-Annually	22	1.44%
BRSC.L	Dividend Knight	2023-05-18	Semi-Annually	47	1.21%
PFD.L	Dividend Knight	2023-06-29	Sporadic	20	0.70%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.124	1.500	7.53	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0759	1.200	7.47	8.96	[0 - 0.3]
returnOnEquityTTM	0.118	1.500	9.80	10.00	[0.1 - 1]
payoutRatioTTM	0.297	-1.000	7.03	-7.03	[0 - 1]
currentRatioTTM	1.797	0.800	6.02	4.81	[1 - 3]
quickRatioTTM	0.422	0.800	-2.23	-1.781	[0.8 - 2.5]
cashRatioTTM	0.0956	1.500	-0.580	-0.870	[0.2 - 2]
debtRatioTTM	0.106	-1.500	8.24	-10.00	[0 - 0.6]
interestCoverageTTM	9.07	1.000	7.75	7.75	[3 - 30]
operatingCashFlowPerShareTTM	18.77	2.00	3.74	7.49	[0 - 30]
freeCashFlowPerShareTTM	13.77	2.00	3.12	6.24	[0 - 20]
debtEquityRatioTTM	0.160	-1.500	9.36	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.437	1.000	6.06	6.06	[0.2 - 0.8]
operatingProfitMarginTTM	0.186	1.000	8.28	8.28	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.127	1.000	4.85	4.85	[0.2 - 2]
assetTurnoverTTM	0.614	0.800	9.24	7.39	[0.5 - 2]
Total Score				10.52

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	4.20	1.000	9.68	0	[1 - 100]
returnOnEquityTTM	0.118	2.50	9.87	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	13.77	2.00	5.41	6.24	[0 - 30]
dividendYielPercentageTTM	0.0466	1.500	8.83	0	[0 - 0.4]
operatingCashFlowPerShareTTM	18.77	2.00	3.74	7.49	[0 - 30]
payoutRatioTTM	0.297	1.500	7.03	-7.03	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.194	1.000	7.64	0	[0.1 - 0.5]
Total Score				5.98

Beximco Pharmaceuticals

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.